These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20686833)

  • 1. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?
    Cameron DA; Douglas S; Brown JE; Anderson RA
    Breast Cancer Res Treat; 2010 Oct; 123(3):805-14. PubMed ID: 20686833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen deficiency and bone loss in women with breast cancer.
    Shapiro CL
    Breast Cancer Res Treat; 2010 Oct; 123(3):815-8. PubMed ID: 20697804
    [No Abstract]   [Full Text] [Related]  

  • 3. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
    Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
    Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy.
    Hopson MB; Onishi M; Awad D; Buono D; Maurer M; Crew KD; Shane E; Hershman DL; Kalinsky K
    Clin Breast Cancer; 2020 Jun; 20(3):e327-e333. PubMed ID: 31926840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy.
    Vehmanen LK; Elomaa I; Blomqvist CP; Saarto T
    Acta Oncol; 2014 Jan; 53(1):75-9. PubMed ID: 23713891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer.
    Hadji P; Ziller M; Maskow C; Albert U; Kalder M
    Eur J Cancer; 2009 Dec; 45(18):3205-12. PubMed ID: 19850468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
    Vehmanen L; Saarto T; Elomaa I; Mäkelä P; Välimäki M; Blomqvist C
    Eur J Cancer; 2001 Dec; 37(18):2373-8. PubMed ID: 11720830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.
    Shapiro CL; Manola J; Leboff M
    J Clin Oncol; 2001 Jul; 19(14):3306-11. PubMed ID: 11454877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    Vehmanen L; Elomaa I; Blomqvist C; Saarto T
    J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer.
    Christensen CØ; Cronin-Fenton D; Frøslev T; Hermann AP; Ewertz M
    Support Care Cancer; 2016 Oct; 24(10):4229-36. PubMed ID: 27146497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
    Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
    Powles TJ; Hickish T; Kanis JA; Tidy A; Ashley S
    J Clin Oncol; 1996 Jan; 14(1):78-84. PubMed ID: 8558225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
    Dieckmeyer M; Ruschke S; Rohrmeier A; Syväri J; Einspieler I; Seifert-Klauss V; Schmidmayr M; Metz S; Kirschke JS; Rummeny EJ; Zimmer C; Karampinos DC; Baum T
    BMC Musculoskelet Disord; 2019 Nov; 20(1):515. PubMed ID: 31694630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chemotherapy and different chemotherapy regimens on bone health among Chinese breast cancer women in different menstrual status: a self-control study.
    Peng BQ; Wu J; Tian S; Qu XQ; Liang XY; Feng JH; Chen YL; She RL; Ma CY; Song JY; Li ZX; Jiang ZY; Wu KN; Kong LQ
    Support Care Cancer; 2023 Aug; 31(9):540. PubMed ID: 37642751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
    Hershman DL; McMahon DJ; Crew KD; Cremers S; Irani D; Cucchiara G; Brafman L; Shane E
    J Clin Oncol; 2008 Oct; 26(29):4739-45. PubMed ID: 18711172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and ovarian function.
    Berliere M; Duhoux FP; Dalenc F; Baurain JF; Dellevigne L; Galant C; Van Maanen A; Piette P; Machiels JP
    PLoS One; 2013; 8(6):e66616. PubMed ID: 23840510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
    Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
    Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.